Pfizer To Pay $345 Million In EpiPen Anti-Trust Lawsuit

Reuters reports:

Pfizer Inc has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anti-competitive and unfair practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan.

The proposed class action settlement was disclosed in a filing in federal court in Kansas City, Kansas. The deal, which requires a judge’s approval, would not resolve claims against Mylan, which is scheduled to face trial in January.

Paul Geller, a lawyer for the plaintiffs, said they were “pleased that Pfizer resolved its part of this class action lawsuit over the pricing of EpiPens.”

Read the full article.